The expression of miR-122 is decreased as liver fibrosis progressed. by Young Chang (3666829)

Handholding does not decrease emotional pain, but does increase comfort. by Razia S. Sahi (10120020)

ATRX-knockdown decreases the deposition of heterochromatin on incoming HCMV genomes. by Ryan M. Walter (19550606)

Inhibition of Cl^- channels decreases CHIKV replication. by Marietta Müller (7345163)

Cell nuclear volume decreases under increasing osmotic pressure. by Adele Khavari (7378082)

ILC2s decrease in blood but remain the same in adipose tissue. by Fred R. Sattler (9338330)

Increases in ground electrode size are associated with decreases in electric field. by Timothy Kim (3699391)

24 hours of ARD results in noticeable decrease in ORO staining. by Moriah Eustice (13813098)

Stopping or Decreasing Opioid Therapy in Patients on Chronic Opioid Therapy by Joseph V. Pergolizzi (4997790)

Pre-exposure to mRNA-LNPs decreases antigen levels. by Zhen Qin (411748)

Turns decrease the likelihood of interneuron evoked reversals, except for AVA. by Sandeep Kumar (145759)

Metronidazole thermogel improves retention and decreases permeation through the skin by Elayne Karine Souto de Melo (12848144)

PGRN decreased Dectin-2 expression on the surface of macrophages and neutrophils. by Jiayu Liu (3951515)

Depletion of ATRX in fibroblasts decreases the efficiency of viral genome packaging. by Ryan M. Walter (19550606)

The protein level of ApoB was decreased in HCV-infected cells. by Bei Wang (116772)

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…These treatment frequencies declined significantly after surgery: at 1 year postoperatively, the averages were 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at 2 years, 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at 3 years, 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g003" target="_blank">Fig 3</a>). …”